Literature DB >> 28839973

Deciding on the neoadjuvant approach for esophageal adenocarcinomas.

Cai Xu1, Steven Hsesheng Lin2.   

Abstract

Entities:  

Year:  2017        PMID： 28839973      PMCID： PMC5542969          DOI： 10.21037/jtd.2017.06.114

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer.

Authors:  S G Swisher; L Deford; K W Merriman; G L Walsh; R Smythe; A Vaporicyan; J A Ajani; T Brown; R Komaki; J A Roth; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2000-06       Impact factor: 5.209

2.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

Review 3.  Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.

Authors:  Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg
Journal:  J Clin Oncol       Date:  2005-03-21       Impact factor: 44.544

4.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

5.  Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.

Authors:  Bryan H Burmeister; Janine M Thomas; Elizabeth A Burmeister; Euan T Walpole; Jennifer A Harvey; Damien B Thomson; Andrew P Barbour; David C Gotley; B Mark Smithers
Journal:  Eur J Cancer       Date:  2011-02       Impact factor: 9.162

6.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

7.  Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?

Authors:  Sheraz Markar; Caroline Gronnier; Alain Duhamel; Arnaud Pasquer; Jérémie Théreaux; Mael Chalret du Rieu; Jérémie H Lefevre; Kathleen Turner; Guillaume Luc; Christophe Mariette
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

8.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

9.  Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Andrew R Davies; James A Gossage; Janine Zylstra; Fredrik Mattsson; Jesper Lagergren; Nick Maisey; Elizabeth C Smyth; David Cunningham; William H Allum; Robert C Mason
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

10.  Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.

Authors:  S R Markar; B J Noordman; H Mackenzie; J M Findlay; P R Boshier; M Ni; E W Steyerberg; A van der Gaast; M C C M Hulshof; N Maynard; M I van Berge Henegouwen; B P L Wijnhoven; J V Reynolds; J J B Van Lanschot; G B Hanna
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.